info@cymabay.com
(510) 293-8800
Home
About
Overview
Management Team
Board of Directors
Careers
Clinical Trials
Pipeline
Overview
Seladelpar
Additional Programs
Expanded Access
Clinical Trials
Collaborations
News
Press Releases
Upcoming Events
Investors
Contact
Investors
Home
/
Investors
/
Press Releases
Press Releases
Overview
News / Events
Press Releases
Events
Presentations
Publications
Email Alerts
Company Information
Profile
Management Team
IR Contacts
FAQ
Financial Information
Financials
Quarterly Results
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Corporate Governance
Board of Directors
Board Committees
Governance Docs
Email Alerts
IR Contacts
RSS News Feed
All News
By Year:
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
12
Apr
CymaBay Therapeutics Presents Positive Phase 2 Data for Seladelpar in Patients with Primary Biliary Cholangitis at the International Liver Congress™ 2019
27
Mar
CymaBay Therapeutics Announces Multiple Presentations During The International Liver Conference™ 2019
12
Mar
CymaBay Therapeutics to Present at Upcoming Investor Conferences in March
11
Mar
CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
6
Mar
CymaBay Announces Pricing of Public Offering of Common Stock
5
Mar
CymaBay Announces Proposed Public Offering of Common Stock
28
Feb
CymaBay Reports Fourth Quarter and Fiscal Year End 2018 Financial Results and Provides Corporate Update
21
Feb
CymaBay Therapeutics to Report Fourth Quarter and Fiscal 2018 Financial Results on Thursday, February 28
20
Feb
CymaBay Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference
19
Feb
CymaBay Therapeutics Announces Early Enrollment of a Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis
<< Previous
1
2
3
4
Next >>
Show All
Scroll
